Sector News

Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal

May 13, 2019
Life sciences

Takeda is looking to lighten the huge debt burden from the Shire buyout. Novartis wants to beef up its eye medicine portfolio after the Alcon spinoff. Now, the two companies have found a deal where their needs align.

As previously rumored, Takeda is selling Shire’s dry-eye drug Xiidra. To take it in, Novartis is shelling out $3.4 billion upfront and commits potential milestone payments of up to $1.9 billion, and gets a therapy that “fits strategically” with its ophthalmic pharmaceutical portfolio, the Swiss drugmaker said Thursday.

The pair expect the deal to close in the second half of this year. Once that happens, nearly 400 Takeda employees associated with Xiidra and based mainly in the U.S. and Canada will come over to Novartis.

Xiidra, which competes against Allergan’s Restasis, generated sales of about $400 million last year and is “well positioned for blockbuster potential,” Novartis said. In 2018, Novartis’ entire ophthalmology medicine franchise, led by Roche-shared blockbuster wet age-related macular degeneration therapy Lucentis, returned $4.56 billion, down 1% over the previous year mainly due to generic erosions to its intraocular hypertension drug Travatan and pink eye therapy Pataday.

“Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients,” Novartis’ pharma chief Paul Hudson said in a statement. “We look forward to leveraging our well-established commercial infrastructure to bring this medicine to more patients.”

Novartis has its own dry eye therapy in development: ECF843, a recombinant form of human lubricin in-licensed from Lubris in 2017, is in phase 2 with a planned first regulatory submission in 2022. Through a deal in late 2016, Novartis took in Encore Vision and its UNR844, a potentially first-in-class topical treatment for presbyopia. The Swiss drugmaker is counting on the Xiidra team’s commercial experience to help with those front-of-the-eye pipeline products.

For Takeda, the Xiidra deal marks the first selloff since the $62 billion Shire takeover. The Japanese pharma is hoping to divest around $10 billion worth of products to help cut down debt incurred with the acquisition. Other rumored or confirmed castoffs include its European over-the-counter business, its entire Latin American unit, Shire’s hypoparathyroidism drug Natpara, and a Shire inflammatory bowel disease candidate.

Separately, Takeda also said it will sell TachoSil surgical patch to Johnson & Johnson’s Ethicon for about $400 million. For the fiscal year ended last March, Takeda recorded $155 million sales for TachoSil. Together with the product, about 80 employees will join J&J. But Takeda will keep a manufacturing facility in Linz, Austria, that makes the TachoSil and will continue to supply it for J&J under a long-term agreement, Takeda said on Wednesday.

“These initial divestitures represent important steps in advancing the growth strategy Takeda outlined following our transformational acquisition of Shire earlier this year,” Takeda CEO Christophe Weber said in a statement. The company is sharpening its focus on the core areas of gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach